<DOC>
	<DOCNO>NCT03020992</DOCNO>
	<brief_summary>The purpose study demonstrate effect Certolizumab Pegol ( CZP ) treatment reduction Anterior Uveitis ( AU ) flare subject active axial Spondyloarthritis ( axSpA ) document history AU</brief_summary>
	<brief_title>A Study Assess Effects Certolizumab Pegol Reduction Anterior Uveitis ( AU ) Flares Axial Spondyloarthritis Subjects With Documented History AU</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Uveitis , Anterior</mesh_term>
	<mesh_term>Iridocyclitis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>1 . Subjects must document diagnosis adultonset axial Spondyloarthritis ( axSpA ) least 3 month ' symptom duration meet Assessment SpondyloArthritis International Society ( ASAS ) criteria 2 . Subjects must active disease Screening define Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) score &gt; = 4 Spinal pain &gt; = 4 0 10 Numerical Rating Scale ( NRS ; BASDAI item 2 ) Nonradiographic ( Nr ) axSpA subject must either Creactive protein ( CRP ) &gt; upper limit normal ( ULN ) /or current evidence sacroiliitis magnetic resonance imaging ( MRI ) ( confirmation central reading ) define ASAS criterion Ankylosing spondylitis ( AS ) subject must evidence sacroiliitis xray meeting modify New York ( mNY ) criterion accord Investigator 3 . Subjects must document history Anterior Uveitis ( AU ) diagnose ophthalmologist least 2 AU flare past , least 1 AU flare last 12 month prior Baseline Other inflammatory arthritis Secondary , noninflammatory condition , Investigator 's opinion , symptomatic enough interfere evaluation effect study drug subject 's primary diagnosis axial spondyloarthritis ( axSpA ) Any history uveitis except Anterior Uveitis ( AU ) associate axSpA Any condition complicate factor may interfere AU assessment Retisert® Iluvien® ( glucocorticosteroid implant ) within 3 year prior Baseline Visit complication related device Subject Retisert Iluvien ( glucocorticosteroid implant ) remove within 90 day prior Baseline Visit Intraocular periocular corticosteroid within 90 day prior Baseline visit Ozurdex® ( dexamethasone implant ) within 6 month prior Baseline Visit Cyclophosphamide within 30 day prior Baseline Visit Intravitreal methotrexate ( MTX ) within 90 day prior Baseline Visit Intravitreal antivascular endothelial growth factor ( VEGF ) therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Axial Spondyloarthritis</keyword>
	<keyword>axSpA</keyword>
	<keyword>Anterior Uveitis</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>